Imugene Limited
IUGNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -11.5% | -57.8% | -9.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 81.3% | 81.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,533.5% | -2,977.4% | -402.7% | -272.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,569.8% | -3,011.7% | -321.9% | -292% |
| EPS Diluted | -0.32 | -0.72 | -0.21 | -0.23 |
| % Growth | 55.6% | -242.9% | 8.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |